SEATTLE and ORLANDO, Fla. — Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) announced today the presentation of encouraging Phase 1 safety and efficacy results following administration of low doses of TRU-016 in heavily pre-treated patients with high-risk genomic factors and relapsed or refractory chronic lymphocytic leukemia (CLL). TRU-016 is the Company’s proprietary...
Latest News
STOCKHOLM, Sweden – Sobi® (STO: SOBI), a global biopharmaceutical company dedicated to delivering innovative treatments for patients with rare diseases, and Ionis Pharmaceuticals, Inc. today announced that Tryngolza® (olezarsen) has been approved in the European Union (EU) as an adjunct to diet in adult patients for the treatment of genetically...
Stockholm, Sweden – Sobi® (STO: SOBI) and Ionis Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion of TRYNGOLZA® (olezarsen) as an adjunct to diet in adult patients for the treatment of genetically confirmed familial...
KELOWNA, Canada – Tryp Therapeutics Inc., a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, is pleased to announce that the first patient has been dosed in a Phase 2a clinical trial being conducted by the University of...
WALTHAM, Mass. — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the first patient has been infused with TSC-101 in the pivotal Phase 3 ALLOHA-2™ trial...
BAAR, Switzerland — Novocure (NASDAQ: NVCR) announced today that the province of British Columbia, Canada, will now cover Tumor Treating Fields (TTFields) therapy for the treatment of adult patients with newly diagnosed glioblastoma. British Columbia is the first province to provide coverage following Canada’s Drug Agency’s assessment and reimbursement recommendation...
Researchers at Tulane University, in collaboration with Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, have received a five-year $7.07 million grant from the National Institutes of Health (NIH) for continued development of detection kits for Lassa viral hemorrhagic fever, a serious disease spread by contact...
New Orleans, Louisiana – Researchers at Tulane University have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people worldwide. IPF is rapidly progressive and causes scarring in the lungs, making it difficult to breathe....
Munich, Germany – Tumors actively prevent the formation of immune responses by so-called cytotoxic T cells, which are essential in combating cancer. Researchers at the Technical University of Munich (TUM) and the Ludwig-Maximilians-Universität München (LMU) Hospital have now uncovered for the first time how this exactly happens. The study in...
Mountain View, Calif. — Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, announced that Anja Krammer, Chief Executive Officer, will present a corporate overview at the Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days on Tuesday, April 4, 2023 at 1 p.m....